Volpara (ASX:VHT) share price soars on 5-year contract

The ASX healthcare share Volpara Health Technologies Ltd (ASX: VHT) has revealed an exciting contract in the US.

You’re reading a free article on Rask. Join 4,000+ Australians who get our expert advice, tools, exclusive research and investment recommendations. Get your 30-day trial for $1! Learn more

The ASX healthcare share Volpara Health Technologies Ltd (ASX: VHT) has revealed an exciting contract. The Volpara share price has jumped 5%.

Volpara is a technology business that is primarily involved in helping identifying and protecting against cancer as early as possible.

Volpara’s great new contract

online pharmacy mobic for sale with best prices today in the USA

It revealed that it had signed a five-year contract with Banner Health, one of the largest non-profit hospital systems in the US. Banner Health operates 30 hospitals, including three academic medical centres.

This contract represents an additional US$1.25 million of total contract value (TACV).

The contract expansion includes upgrades and new installations of Volpara’s patient hub, analytics and risk pathways software across the Banner Health network.

Volpara said that the installation is expected to be completed within the next nine months. It includes annual payments is expected to “contribute to revenue growth in FY24”.

Management commentary

The Volpara CEO Teri Thomas said:

We are proud to expand our relationship with Banner Health and extend Volpara software to all their locations. This standardisation of care and implementation of new capabilities will help deliver more personalised care, find more cancers and identify high risk patients sooner so they can receive recommended interventions. We look forward to working with Banner Health to help save more families from cancer.

Thoughts on this for the Volpara share price

Clearly it’s a great step forward. To be recognised and chosen by such a large institution is very encouraging thing just by itself. But it could also be the start of being picked by more large US healthcare providers.

With such a strong gross profit margin, of over 90%, any revenue growth is highly helpful to the financials. This is a good boost to the company’s financial profile.

I think the business could be one of the best performing ASX shares over the rest of this decade, particularly if it’s able to make some progress with its lung cancer screening segment.

I believe it’s one of the most promising ASX growth shares to buy today.

CSL, Xero, ANZ... the ASX is beaten up

Right now, only brave investors are buying. Is ASX Reporting Season your KEY opportunity to act? Buy, or sell.

This coming Monday night, our two most experienced professional investors, Owen Rask and Leigh Gant, are hosting an exclusive and rare webinar on the what to watch this ASX reporting season. LIVE and free

With over 35 years of combined investing experience, join our Chief Investment Officer and Head of Content for our free Q&A.

We’ll be diving into results from CSL, Pro Medicus (ASX: PME), ANZ Bank and more. It’s absolutely free to join us. Take advantage of this volatility with our free playbook. Simply click here to view the topics.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.

A $50,000 per year passive income special report

Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.

How can Rask help you?

About Rask

Learn more about us, our your community and our mission.

Rask investing philosophy

Nearly 15 years later.
It's still a work in progress.

Online investment community

You won't find our investment community on Facebook or Reddit because it's secure, free and available now.

Join 250,000+ podcast listeners

250,000 investors tune into the Rask podcasts every month. Find out why.

Find a financial planner

Australia's financial experts. At your doorstep.

Free finance courses

35,000 students have enrolled in free Rask courses. We're on a mission to 100,000.

Subscribe to Rask's free investor newsletter

53,000 Australian investors subscribe to our Sunday newsletter... and love it! It's free.

$50 million invested

We manage almost $50 million on behalf of Aussies. Discover how you can invest with us.

Better investing starts here.

Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best  insights.

Subscribe to Rask's free investor newsletter

Kick off your week with our pick of podcasts, courses and investing resources to keep your finger on the Rask pulse!

Here you go: A $50,000 per year passive income special report

Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.

Simply enter your email address and we’ll send it to you. No tricks. Unsubscribe anytime.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.